B-lactoglobulin-Modified Mesoporous Silica Nanoparticles, A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostate Cancer Cells
Fenbendazole, which is an anthelmintic, was encapsulated into succinylated beta-lactoglobulin-modified, amine-functionalised mesoporous silica nanoparticles to protect the drug throughout gastrointestinal tract and improve its anticancer effects against prostate cancer.
The data resulting from this study include the Higuchi kinetic model of the drug release and the toxicity effects of the prepared formulations against HEK-293 cells.
Geographical area of data collection
Cite this collection
Access the data
Data file types
Creative Commons Attribution 4.0 (CC-BY)